Skip to main content
. Author manuscript; available in PMC: 2014 Aug 11.
Published in final edited form as: Ann Intern Med. 2013 Jul 2;159(1):1–12. doi: 10.7326/0003-4819-159-1-201307020-00003

Figure 2. Glycemic effects of salsalate.

Figure 2

HbA1c (A) and FBG (C) levels are graphed as unadjusted means and 95% CIs. In panel A, the numbers of participants analyzed for the primary end point of HbA1c levels at each time point are displayed below study week. Mild hypoglycemia events (B) and notifications for hyperglycemia (D) sent to the primary caregivers are based on HbA1c levels >10.5% before week 24 and >9.5% after week 24. Participants could have >1 mild hypoglycemic event or exceed the hyperglycemic threshold >1 time during the trial. FBG = fasting blood glucose; HbA1c = hemoglobin A1c.